UK Court Ruling Ends Novartis/Bayer Crusade Against Avastin In AMD
Off-Label Use Does Not Undermine Licensing System
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.
